TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32223960

Group type: EXPERIMENTAL
Intervention: Women (6-month MACEs)
Number of subjects: 8958

Group type: COMPARATOR
Intervention: Men (6-month MACEs)
Number of subjects: 8958

Group type: EXPERIMENTAL
Intervention: Women (total mortality)
Number of subjects: 8958

Group type: COMPARATOR
Intervention: Men (total mortality)
Number of subjects: 8958

Group type: EXPERIMENTAL
Intervention: Cardiovascular risk profile
Number of subjects: 8958

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 8958

Group type: EXPERIMENTAL
Intervention: Low level of education and socioeconomic status
Number of subjects: 8958

Group type: EXPERIMENTAL
Intervention: Overall factors
Number of subjects: 8958
Study: 32224030

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPIs)
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Non-Glycoprotein IIb/IIIa inhibitors (non-GPI)
Number of subjects: 1329
Study: 32224306

Group type: EXPERIMENTAL
Intervention: Lurbinectedin (3.2 mg/m²)
Number of subjects: 105
Study: 32224416

Group type: EXPERIMENTAL
Intervention: Toripalimab (10 mg/kg Q2W)
Number of subjects: 33
Study: 32224490

Group type: EXPERIMENTAL
Intervention: Full-strength rice suji with green banana
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Full-strength rice suji alone
Number of subjects: 145

Group type: COMPARATOR
Intervention: Three-quarter-strength rice suji
Number of subjects: 145
Study: 32225136

Group type: EXPERIMENTAL
Intervention: MS-Fit training program (standardized, ambulatory, hospital-based circuit training) performed two hours, twice weekly, for two months.
Number of subjects: 55
Study: 32226189

Group type: EXPERIMENTAL
Intervention: Alginate enriched bread
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 0
Study: 32226634

Group type: EXPERIMENTAL
Intervention: Client-centred lifestyle and behavioural intervention, details on dosage and duration not specified.
Number of subjects: 0
Study: 32226774

Group type: EXPERIMENTAL
Intervention: Combined long-term androgen deprivation and pelvic radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32227570

Group type: EXPERIMENTAL
Intervention: Individualized prophylaxis (IP) regimen
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Weekly prophylaxis, modified prophylaxis, or episodic treatment
Number of subjects: 211
Study: 32228157

Group type: EXPERIMENTAL
Intervention: Multimodal enhanced brain function index
Number of subjects: 0
Study: 32228297

Group type: EXPERIMENTAL
Intervention: Progression group (AAA with >10-mL increase in volume)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Stable group (AAA with ≤10-mL increase in volume)
Number of subjects: 126
Study: 32228542

Group type: EXPERIMENTAL
Intervention: HIV-1 exposed uninfected (HEU) children
Number of subjects: 345

Group type: COMPARATOR
Intervention: HIV-unexposed uninfected (HUU) children
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: HEU children with caregivers' DMFT>0
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: HEU children with dmft>0
Number of subjects: 345
Study: 32228611

Group type: EXPERIMENTAL
Intervention: Total joint replacement of the TMC joint
Number of subjects: 287
Study: 32228664

Group type: EXPERIMENTAL
Intervention: Gentamicin-impregnated biologic graft
Number of subjects: 24
Study: 32229096

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 557
Study: 32231244

Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) for primary MN
Number of subjects: 3782
Study: 32231600

Group type: EXPERIMENTAL
Intervention: Actigraphy-based validation of the Sleep Disorder Inventory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleep Disorder Inventory
Number of subjects: 0
Study: 32231633

Group type: EXPERIMENTAL
Intervention: Conventional bone conduction hearing implant system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less invasive treatment with new abutment technology
Number of subjects: 0
Study: 32232048

Group type: EXPERIMENTAL
Intervention: Patient positioning during surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group positioning during surgery
Number of subjects: 0
Study: 32232087

Group type: EXPERIMENTAL
Intervention: Wavelet decomposition method applied to raw voltage data to generate mean wavelet power (MWP) features.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean wavelet power (MWP) features used as input to support vector machine based decoding algorithms.
Number of subjects: 0
Study: 32232095

Group type: EXPERIMENTAL
Intervention: Vibrotactile treatment at the cymba concha
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Vibrotactile treatment in RA patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vibrotactile treatment at the gastrocnemius
Number of subjects: 34
Study: 32232101

Group type: EXPERIMENTAL
Intervention: tsDCS+pDCS
Number of subjects: 26

Group type: COMPARATOR
Intervention: sham
Number of subjects: 26
Study: 32232107

Group type: EXPERIMENTAL
Intervention: Microcurrent treatment administered at home for 5 mins daily for 4 weeks.
Number of subjects: 30
Study: 32232108

Group type: EXPERIMENTAL
Intervention: Closed-loop neuromuscular electrical stimulation using textile-based electrodes
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Textile-based electrodes
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Closed-loop control methods
Number of subjects: 5
Study: 32232175

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (200-285 mmHg cuff pressure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-remote ischaemic conditioning (20 mmHg cuff pressure)
Number of subjects: 0
Study: 32232325

Group type: EXPERIMENTAL
Intervention: Germline CDKN1B variants (pathogenic/likely pathogenic) identified in 3 patients and variants of uncertain significance in 2 patients, accounting for 2.6% of the patients screened.
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Germline CDKN1B variants
Number of subjects: 211
Study: 32232327

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 29
Study: 32232380

Group type: EXPERIMENTAL
Intervention: High-fat overfeeding (65% total energy from fat, 50% above estimated energy requirements) for 7 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-fat overfeeding
Number of subjects: 15
Study: 32232399

Group type: EXPERIMENTAL
Intervention: Kisspeptin stimulation test
Number of subjects: 16
Study: 32232597

Group type: EXPERIMENTAL
Intervention: Caffeine-containing supplement (200 mg caffeine, 1600 mg β-alanine, 1000 mg quercetin) taken 35 minutes before exercise
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study: 32232640

Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Nephrotic range proteinuria
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D deficiency
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Glomerulonephropathy as the origin of CKD
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Overweight or obese body mass index z-score
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Elevated proteinuria
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Hypocalcemia
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D deficiency
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate stage 3b or higher
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Hyperphosphatemia
Number of subjects: 356
Study: 32232740

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) in combination with methotrexate (MTX)
Number of subjects: 444
Study: 32232817

Group type: EXPERIMENTAL
Intervention: Palivizumab administration during RSV season
Number of subjects: 25003
Study: 32232853

Group type: EXPERIMENTAL
Intervention: Severe sepsis or septic shock
Number of subjects: 250827

Group type: COMPARATOR
Intervention: Nonsepsis ICU patients
Number of subjects: 250827
Study: 32233700

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (65 pregnant women without complications)
Number of subjects: 75
Study: 32233741

Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment
Number of subjects: 303

Group type: COMPARATOR
Intervention: No antihypertensive treatment
Number of subjects: 303
Study: 32233746

Group type: EXPERIMENTAL
Intervention: ASPECTS 8-10
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: ASPECTS 5-7
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Higher ASPECTS (8-10)
Number of subjects: 142

Group type: COMPARATOR
Intervention: ASPECTS and core infarction volume
Number of subjects: 142
Study: 32233756

Group type: EXPERIMENTAL
Intervention: Total nut consumption increase (≥0.5 servings/day)
Number of subjects: 192655

Group type: EXPERIMENTAL
Intervention: Total nut consumption increase (0.5 servings/day)
Number of subjects: 192655

Group type: COMPARATOR
Intervention: Decrease in nut consumption (≥0.50 servings/day)
Number of subjects: 192655
Study: 32233956

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Number of subjects: 0
Study: 32234045

Group type: EXPERIMENTAL
Intervention: Stress cardiovascular magnetic resonance (CMR) screening for silent myocardial ischaemia
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 63
Study: 32234046

Group type: EXPERIMENTAL
Intervention: Patients with PDDI
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Moderate PDDI
Number of subjects: 524

Group type: COMPARATOR
Intervention: Patients in Germany
Number of subjects: 524
Study: 32234077

Group type: EXPERIMENTAL
Intervention: Hyperoxemia on day 1
Number of subjects: 2005

Group type: EXPERIMENTAL
Intervention: Excessive oxygen use
Number of subjects: 2005

Group type: EXPERIMENTAL
Intervention: Hyperoxemia and excessive oxygen use
Number of subjects: 2005
Study: 32234414

Group type: EXPERIMENTAL
Intervention: Supraposture-focus strategy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Posture-focus strategy
Number of subjects: 30
Study: 32234475

Group type: EXPERIMENTAL
Intervention: Dectin-1 on myeloid cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mannose receptor (MR) deficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dectin-1 expression in DSS-exposed MR-deficient mice
Number of subjects: 0
Study: 32234705

Group type: EXPERIMENTAL
Intervention: Intravenous rituximab
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 32234708

Group type: EXPERIMENTAL
Intervention: App-based mindfulness program
Number of subjects: 34
Study: 32234747

Group type: EXPERIMENTAL
Intervention: Yoga of Stress Resilience programme (group-based therapeutic yoga combining yoga and psychotherapeutic techniques)
Number of subjects: 0
Study: 32234848

Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)-based immunotherapy
Number of subjects: 9
Study: 32234967

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 6148
Study: 32235248

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 214
Study: 32236104

Group type: EXPERIMENTAL
Intervention: Peer counseling
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Social engagement
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Combination
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control
Number of subjects: 264
Study: 32236406

Group type: EXPERIMENTAL
Intervention: Isavuconazole (ISAV) as primary antifungal prophylaxis (PAP)
Number of subjects: 65
Study: 32236416

Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 expression on CD4+/CD8+ T cells in mid-PR phase
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: PD-1 expression on CD8+ T cells in mid-PR
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Circulating Tregs and IL-35+ Tregs
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 expression on T cells
Number of subjects: 98

Group type: COMPARATOR
Intervention: Nonremitters
Number of subjects: 98
Study: 32236441

Group type: EXPERIMENTAL
Intervention: Arginine infusion
Number of subjects: 146
Study: 32236525

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of urinary-derived human chorionic gonadotropin (uhCG) in addition to standard immunosuppression
Number of subjects: 26
Study: 32236717

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC) procedure
Number of subjects: 619
Study: 32236732

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ertugliflozin (glimepiride or placebo)
Number of subjects: 0
Study: 32236819

Group type: EXPERIMENTAL
Intervention: Ca/P ratio above 2.55 for PHPT patients
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Ca/P ratio below 1.78 for HypoPT patients
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Ca/P ratio in PHPT patients
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Ca/P ratio in HypoPT patients
Number of subjects: 1038
Study: 32236861

Group type: EXPERIMENTAL
Intervention: Missense variant rs17117699 in OMA1 in group without β-blocker use
Number of subjects: 3324

Group type: COMPARATOR
Intervention: Missense variant rs17117699 in OMA1 in group with β-blocker use
Number of subjects: 3324

Group type: EXPERIMENTAL
Intervention: Functional analysis of rs17117699-G allele
Number of subjects: 3324

Group type: COMPARATOR
Intervention: Functional analysis of rs17117699-T allele
Number of subjects: 3324
Study: 32237015

Group type: EXPERIMENTAL
Intervention: Higher Cardiorespiratory Fitness (CRF)
Number of subjects: 115
Study: 32238160

Group type: EXPERIMENTAL
Intervention: Increased hospital volume
Number of subjects: 759928

Group type: EXPERIMENTAL
Intervention: Decreased hospital volume
Number of subjects: 759928

Group type: COMPARATOR
Intervention: Unchanged hospital volume
Number of subjects: 759928
Study: 32238340

Group type: EXPERIMENTAL
Intervention: Automated Respiratory Infection Diagnostic Aid (ARIDA)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Two ARIDA devices
Number of subjects: 290
Study: 32238341

Group type: EXPERIMENTAL
Intervention: Real-time feedback via the point-of-care (POC) urine test
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care adherence counseling
Number of subjects: 100
Study: 32238343

Group type: EXPERIMENTAL
Intervention: mDASHNa-CC app
Number of subjects: 60
Study: 32238515

Group type: EXPERIMENTAL
Intervention: Tacrolimus maintenance therapy
Number of subjects: 1355
Study: 32238921

Group type: EXPERIMENTAL
Intervention: MRX34 with oral dexamethasone premedication, given intravenously daily for 5 days in 3-week cycles.
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: MRX34 treatment with dexamethasone premedication
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: MRX34
Number of subjects: 85
Study: 32239137

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 149
Study: 32239319

Group type: EXPERIMENTAL
Intervention: Low FVC participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal spirometry participants
Number of subjects: 0
Study: 32239476

Group type: EXPERIMENTAL
Intervention: r-hGH delivered with Easypod™
Number of subjects: 147
Study: 32239971

Group type: EXPERIMENTAL
Intervention: e-Device (ava®) for self-injection of certolizumab pegol (CZP)
Number of subjects: 67
Study: 32240454

Group type: EXPERIMENTAL
Intervention: Trastuzumab SC administered at home by a healthcare professional (HCP)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Trastuzumab SC administered at home
Number of subjects: 102
Study: 32240629

Group type: EXPERIMENTAL
Intervention: Once-weekly rifapentine (900 mg) plus isoniazid (900 mg) for 12 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg daily) for 8 weeks prior to rifapentine-isoniazid
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Adverse events (grade 3 or higher)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: HIV viral loads measured at baseline and at weeks 11 and 24
Number of subjects: 61
Study: 32240793

Group type: EXPERIMENTAL
Intervention: CC-90010 (45 mg, 4 days on/24 days off)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CC-90010 (various doses)
Number of subjects: 69
Study: 32240796

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg (tablets) or 600 mg (capsules) b.i.d.
Number of subjects: 55
Study: 32240908

Group type: EXPERIMENTAL
Intervention: SPECT/CT-guided elective nodal irradiation (ENI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bilateral elective nodal irradiation (B-ENI)
Number of subjects: 50
Study: 32241310

Group type: EXPERIMENTAL
Intervention: 5-HT4 receptor agonists
Number of subjects: 0
Study: 32241317

Group type: EXPERIMENTAL
Intervention: Preparation for end of life factors (knowledge of dementia, social support, feeling supported by healthcare providers, formalized end of life documents, end-of-life discussions)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MMCGI-SF subscales
Number of subjects: 150
Study: 32241330

Group type: EXPERIMENTAL
Intervention: Women with depression
Number of subjects: 419

Group type: COMPARATOR
Intervention: Women without depression
Number of subjects: 419
Study: 32241548

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy (HFNO)
Number of subjects: 60
Study: 32241904

Group type: EXPERIMENTAL
Intervention: Microbiota from patients with ESRD transplanted to renal injured germ-free mice or antibiotic-treated rats
Number of subjects: 223

Group type: COMPARATOR
Intervention: Microbiota from healthy controls
Number of subjects: 223
Study: 32242035

Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal low energy shock wave therapy (LiESWT)
Number of subjects: 50
Study: 32242358

Group type: EXPERIMENTAL
Intervention: KTE-X19 CAR T-cell therapy
Number of subjects: 74
Study: 32242498

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 0
Study: 32242768

Group type: EXPERIMENTAL
Intervention: Intravascular Lithotripsy
Number of subjects: 0
Study: 32243379

Group type: EXPERIMENTAL
Intervention: Healthy intervention group receiving 2 sessions of moxibustion in the Heart meridian and Lung meridian.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy control group and chronic stable angina pectoris group.
Number of subjects: 120
Study: 32243941

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 489
Study: 32243960

Group type: EXPERIMENTAL
Intervention: NS5A-containing DAA therapy
Number of subjects: 642
Study: 32244368

Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 42

Group type: COMPARATOR
Intervention: Increased dose of unfractionated heparin (UFH)
Number of subjects: 42
Study: 32245397

Group type: EXPERIMENTAL
Intervention: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir (3D) ± Ribavirin for 12 or 24 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study: 32245502

Group type: EXPERIMENTAL
Intervention: Bispecific CAR T cell therapy targeting CD19 and CD22
Number of subjects: 6
Study: 32245906

Group type: EXPERIMENTAL
Intervention: PAN-PROMISE scale (patient-reported outcome measure)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: PAN-PROMISE scale
Number of subjects: 524
Study: 32246266

Group type: EXPERIMENTAL
Intervention: Balloon-expandable valve (BEV; Sapien 3)
Number of subjects: 56
Study: 32246968

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus for atopic dermatitis (used for ≥6 weeks)
Number of subjects: 7954

Group type: COMPARATOR
Intervention: Matched background data from national cancer registries
Number of subjects: 7954
Study: 32247041

Group type: EXPERIMENTAL
Intervention: Quadrivalent human papillomavirus (qHPV) vaccine
Number of subjects: 0
Study: 32247206

Group type: EXPERIMENTAL
Intervention: Extreme hypofractionated doses of 35 Gy in 5 weekly fractions to the whole prostate gland with an integrated boost up to 50 Gy to the mpMRI-defined tumour(s)
Number of subjects: 100
Study: 32248659

Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST) 90 mg subcutaneously at baseline and at weeks 4, 12, 20, 28, 36, and 44, combined with a 24-week prednisone taper.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST) with 24 weeks of prednisone.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Alternative definition of prednisone-free remission (not requiring ESR/CRP normalization).
Number of subjects: 13
Study: 32248819

Group type: EXPERIMENTAL
Intervention: Percutaneous mitral commissurotomy (PMC)
Number of subjects: 40
Study: 32249038

Group type: EXPERIMENTAL
Intervention: PRIMA wireless photovoltaic retinal implant
Number of subjects: 5
Study: 32249039

Group type: EXPERIMENTAL
Intervention: Prediction model incorporating age, sex, BMI, CTX-II, and KL-grade
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Cumulative KL-grade between knees of 5, 6, or 7
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Age (per 5 years)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Baseline u-CTX-II
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Composite model (age, sex, BMI, u-CTX-II, KL-grade)
Number of subjects: 1255
Study: 32249045

Group type: EXPERIMENTAL
Intervention: Lumbar drain placement
Number of subjects: 100
Study: 32249139

Group type: COMPARATOR
Intervention: Metabolically healthy obese subjects
Number of subjects: 3325

Group type: COMPARATOR
Intervention: Metabolically unhealthy subjects (regardless of obesity status)
Number of subjects: 3325

Group type: EXPERIMENTAL
Intervention: Metabolic unhealthiness
Number of subjects: 3325

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 3325

Group type: EXPERIMENTAL
Intervention: Metabolic unhealthiness in nonobese subjects
Number of subjects: 3325
Study: 32249170

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Non-Drug-Coated Balloon (non-DCB)
Number of subjects: 327
Study: 32249171

Group type: EXPERIMENTAL
Intervention: Prescribing hormonal contraception
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Training needs, reimbursement, and liability
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Availability of private areas, pharmacists' role as knowledgeable health care team members, and pharmacist accessibility without appointments
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Over-the-counter access to hormonal contraception
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Certification to prescribe and place subdermal contraceptive implants
Number of subjects: 25
Study: 32250312

Group type: EXPERIMENTAL
Intervention: UniQure AMT-130
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurocrine Biosciences KINECT-HD
Number of subjects: 0
Study: 32250517

Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg single-agent
Number of subjects: 22
Study: 32250561

Group type: EXPERIMENTAL
Intervention: Pilates exercise
Number of subjects: 30